Contributors

Ken Hallenbeck

Ken Hallenbeck

Ken Hallenbeck earned a Ph.D. in pharmaceutical sciences from the University of California, San Francisco, and now is an early drug-discovery researcher. He loves to think and write about the future of scientific research. He serves on the board of directors of ReImagine Science, a nonprofit that empowers and connects scientist advocates, and is the life sciences lead at TerraPrime, a consulting firm that works with start-ups that aim to disrupt the scientific publication and education ecosystems.
 

Articles by Ken Hallenbeck

The evolution of proteins from mysteries to medicines
Essay

The evolution of proteins from mysteries to medicines

Feb. 27, 2021
An essay in observance of National Protein Day.
The COVID-19 deluge: Is it time for a new model of data disclosure?
Life in the Lab

Time for a new model of data disclosure?

July 15, 2020
Ken Hallenbeck asserts that a flood of scientific papers related to the pandemic provides an opportunity to review core assumptions of the modern publication model.